FDA panel: Not enough data to OK "abuse-deterrent" opioid

A panel of Food and Drug Administration advisers voted against approving a new opioid painkiller with a unique feature for deterring abuse: It releases a deep-blue dye if someone tries to get high by crushing, chewing or snorting pills.

Panelists voted overwhelmingly against approving Intellipharmaceutics International's generic version of extended-release Oxycontin, a key in the U.S. addiction epidemic. The FDA usually follows its advisers' advice.

Doctors and scientists raised many concerns about the dye's safety for intended patients, and its effectiveness in deterring opioid abusers. Most said the company hadn't done enough studies of the drug.

Some suggested blue stains around the mouth or nose from trying to abuse the drug could become popular among addicts. Others said the dye's "Scarlet Letter" shaming approach was insensitive.


Explore further

FDA asks maker of opioid painkiller opana ER to pull drug from market

© 2017 The Associated Press. All rights reserved.

Citation: FDA panel: Not enough data to OK "abuse-deterrent" opioid (2017, July 26) retrieved 20 March 2019 from https://medicalxpress.com/news/2017-07-fda-panel-abuse-deterrent-opioid.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more